...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients
【24h】

Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients

机译：前列腺素I2类似物与抗血小板药物在血液透析患者外周动脉疾病之间的随机先导试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The effect of the prostaglandin I2 analog, beraprost sodium (BPS), on hemodialysis (HD) patients with peripheral arterial disease (PAD) has not been fully elucidated. The effect of BPS was compared to that of PAD drugs in HD patients with PAD in a multicenter randomized prospective interventional pilot study (J-PADD). Seventy-two PAD patients on HD were entered and randomly divided into two groups; that is, BPS group (Group A: n=35) and PAD drug (cilostazol or sarpogrelate) group (Group B: n=37). Primary endpoint was changes in skin perfusion pressure (SPP). Kidney Disease Quality of Life (KDQOL) score, cardiovascular events, PAD events, and adverse events were also evaluated. SPP increased significantly in both groups at 24 weeks from their basal levels. The absolute increase of SPP in Group A and Group B were 15.4±30.0mmHg (P0.0001) and 20.2±22.1mmHg (P=0.025) (instep), and 13.8±19.3mmHg (P0.0001) and 9.2±16.3mmHg (P=0.041) (sole), respectively. Changes of KDQOL score showed significantly better result in the role of physical score in Group A compared with Group B. Although heart rate was unchanged in Group A, 9.3/min increase was seen in Group B patients who received cilostazol. There was no intergroup difference in cardiovascular events and/or PAD events between the two groups during the study period. This exploratory pilot study suggested BPS was as effective as anti-platelet drugs in improving microcirculation in HD patients.
机译：尚未完全阐明前列腺素I2类似物贝拉前列素钠（BPS）对血液透析（HD）伴有外周动脉疾病（PAD）的患者的作用。在一项多中心随机前瞻性干预性试验研究（J-PADD）中，将BPS与PAD药物对HD伴PAD患者的作用进行了比较。进入HD的72名PAD患者被随机分为两组。即BPS组（A组：n = 35）和PAD药物（西洛他唑或sarpogrelate）组（B组：n = 37）。主要终点是皮肤灌注压力（SPP）的变化。还评估了肾脏疾病生活质量（KDQOL）评分，心血管事件，PAD事件和不良事件。两组中的SPP从基础水平开始都显着增加了24周。 A组和B组的SPP绝对升高分别为15.4±30.0mmHg（P <0.0001）和20.2±22.1mmHg（P = 0.025）（脚背），以及13.8±19.3mmHg（P <0.0001）和9.2±16.3mmHg （P = 0.041）（唯一）。与B组相比，A组的KDQOL评分变化显着更好地体现了其物理评分的作用。尽管A组的心率没有变化，但接受西洛他唑的B组患者的心率增加了9.3 / min。在研究期间，两组之间在心血管事件和/或PAD事件方面没有组间差异。这项探索性先导研究表明，BPS在改善HD患者的微循环方面与抗血小板药物一样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号